Clinical Research & Reference Standard Compendium
Incretin + Amylin - Scientific Literature
I. Abstract & Overview
Incretin + Amylin supplies Retatrutide (10 mg) and Cagrilintide (5 mg) as two separately labelled lyophilized vials engaging receptor systems with no structural relationship to each other. Retatrutide is a triple agonist at the GIP, GLP-1 and glucagon receptors; Cagrilintide acts at amylin receptors, which exist only as heterodimers of the calcitonin receptor with a receptor activity-modifying protein. Both are large lipidated analogs above 4400 daltons whose fatty acid side chains govern their handling behaviour. Supplied for Research Use Only.
II. Chemical Specifications
| Molecular Formula | Blend — no single formula applies; Retatrutide C221H342N46O68 and Cagrilintide C194H312N54O59S2 |
|---|---|
| Molar Mass | Retatrutide 4731.3 g/mol; Cagrilintide 4409 g/mol — both above 4400, the heaviest two-vial panel in this range |
| CAS Registry Number | Blend |
| Amino Acid Sequence | Retatrutide, a lipidated triple GIP/GLP-1/glucagon receptor agonist backbone; Cagrilintide, a lipidated long-acting amylin analog |
III. Mechanism & Cellular Signaling Pathways
Retatrutide activates three class B G protein-coupled receptors — GIP, GLP-1 and glucagon — from a single peptide backbone, and Coskun and colleagues described its discovery and receptor profile in 2022. Cagrilintide's targets are structurally different in kind: amylin receptors form when the calcitonin receptor associates with one of three receptor activity-modifying proteins, producing distinct phenotypes from the same core receptor. This means the amylin arm of an experiment is sensitive to the accessory protein complement of the model system, a variable that has no counterpart on the incretin side of the panel.
IV. Primary Research Directions
- Two receptor systems with no structural relationship in one tray — a class B triple agonist alongside a heterodimer-dependent amylin agonist
- Cagrilintide supplied under the correct registry number 1415456-99-3, correcting the sector-wide 141430-65-1 attribution that resolves to an unrelated 371 dalton benzenesulfonamide
- Both components released on observed intact mass and peptide mapping rather than retention time, which lipidated side chains make an unreliable identity signal
- Retatrutide filled at double the Cagrilintide quantity to match its higher consumption across dose-ranging arms
- Handling guidance specific to surface-active lipidated peptides, where visible foaming indicates interface accumulation rather than dispersion
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Coskun, T., Urva, S., Roell, W. C., et al. (2022). 'LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.' Cell Metabolism, 34(9), 1234-1247.e9. DOI: 10.1016/j.cmet.2022.07.013 | PMID: 35985340
- Cao, J., Belousoff, M. J., Liang, Y. L., et al. (2022). 'A structural basis for amylin receptor phenotype.' Science, 375(6587), eabm9609. DOI: 10.1126/science.abm9609 | PMID: 35324283
- Enebo, L. B., Berthelsen, K. K., Kankam, M., et al. (2021). 'Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.' The Lancet, 397(10286), 1736-1748. DOI: 10.1016/S0140-6736(21)00845-X | PMID: 33894838
Incretin + Amylin
Abstract & Overview
Incretin + Amylin supplies Retatrutide (10 mg) and Cagrilintide (5 mg) as two separately labelled lyophilized vials engaging receptor systems with no structural relationship to each other. Retatrutide is a triple agonist at the GIP, GLP-1 and glucagon receptors; Cagrilintide acts at amylin receptors, which exist only as heterodimers of the calcitonin receptor with a receptor activity-modifying protein. Both are large lipidated analogs above 4400 daltons whose fatty acid side chains govern their handling behaviour. Supplied for Research Use Only.
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (Incretin + Amylin) | 11.30 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 11.30 minutes represents the active compound (Incretin + Amylin). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
Retatrutide activates three class B G protein-coupled receptors — GIP, GLP-1 and glucagon — from a single peptide backbone, and Coskun and colleagues described its discovery and receptor profile in 2022. Cagrilintide's targets are structurally different in kind: amylin receptors form when the calcitonin receptor associates with one of three receptor activity-modifying proteins, producing distinct phenotypes from the same core receptor. This means the amylin arm of an experiment is sensitive to the accessory protein complement of the model system, a variable that has no counterpart on the incretin side of the panel.
Primary Research Directions
Two receptor systems with no structural relationship in one tray — a class B triple agonist alongside a heterodimer-dependent amylin agonist
Cagrilintide supplied under the correct registry number 1415456-99-3, correcting the sector-wide 141430-65-1 attribution that resolves to an unrelated 371 dalton benzenesulfonamide
Both components released on observed intact mass and peptide mapping rather than retention time, which lipidated side chains make an unreliable identity signal
Retatrutide filled at double the Cagrilintide quantity to match its higher consumption across dose-ranging arms
Handling guidance specific to surface-active lipidated peptides, where visible foaming indicates interface accumulation rather than dispersion
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Coskun, T., Urva, S., Roell, W. C., et al. (2022). 'LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.' Cell Metabolism, 34(9), 1234-1247.e9. DOI: 10.1016/j.cmet.2022.07.013 | PMID: 35985340
Cao, J., Belousoff, M. J., Liang, Y. L., et al. (2022). 'A structural basis for amylin receptor phenotype.' Science, 375(6587), eabm9609. DOI: 10.1126/science.abm9609 | PMID: 35324283
Enebo, L. B., Berthelsen, K. K., Kankam, M., et al. (2021). 'Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.' The Lancet, 397(10286), 1736-1748. DOI: 10.1016/S0140-6736(21)00845-X | PMID: 33894838
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
